Bright Minds Biosciences to Present at the Stifel GMP Healthcare Conference – Healthcare Psychedelics: Addressing the Global Mental Health Crisis
VANCOUVER, British Columbia, March 10, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer, will be presenting at the Stifel GMP Healthcare Conference – Healthcare Psychedelics: Addressing…
